SMO and medulloblastoma: For longitudinal measurement of pharmacodynamic response, we administered vismodegib to another medulloblastoma-prone genotype, hGFAP-Cre/SmoM2/Gli-luc, that carries a synthetic, SHH-sensitive luciferase reporter construct (G-Smo/Gli-luc; Fig. 1d).